Passage Bio
Philadelphia, United States · Biotechnology, Genetics, Healthcare
Passage Bio, Inc. (NASDAQ: PASG) is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases.
Key facts
- Headquarters
- Philadelphia, United States
- Employees
- 83
- Industries
- Biotechnology, Genetics, Healthcare
- Status
- Public (PASG)
- Website
- comhomedefault.aspx
- Company page
Recent activity at Passage Bio
- : SEC 8-K (1.01): On September 2, 2026, Passage Bio, Inc. entered into an Amended and Restated Merger Agreement with Peregrine Merger Sub, Inc., a wholly owned subsidiary of the Company, and Remix Therapeutics, Inc. This agreement involves a strategic merger designed to advance Passage Bio's capabilities in gene therapy, which is critical for both companies' future product development. The original merger agreement, dated June 24, 2026, lays the foundation for this amendment, enabling Passage Bio to enhance its operational structure and potentially improve market positioning. The merger is subject to specified conditions which if satisfied, could lead to a significant transformation in the combined entities. Details regarding financial terms and implications were not disclosed in this initial filing.
- : Passage Bio to merge with Remix Therapeutics
- : Passage Bio Terminates Lease Agreement with Hopewell Campus Owner LLC
- : Passage Bio, Inc. Reports Interim Data from upliFT-D Study for PBFT02 Treatment of Frontotemporal Dementia.
- : Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
- : Passage Raises $4M To Help Developers Bring Biometric Authentication To The Masses
- : Passage BIO, Inc.
Passage Bio funding history
| Date | Round | Amount |
|---|---|---|
| Feb 2022 | Seed | $4.0M |
| Sep 2019 | Venture | $110.0M |
Leadership
- Justin Poley, Executive Director, Manufacturing Operations.
- Thomas Woiwode, Director
- Saqib Islam, Director
- Tadataka Yamada, Executive Officer, Director, Promoter
- Carl Gordon, Director
- Patrick Heron, Director
- Stephen Squinto, Executive Officer, Director
- Will Chou, Chief Executive Officer
Verified email and direct lines for Passage Bio’s decision-makers are on Fundz. See plans
Companies similar to Passage Bio
- Crispr Therapeutics · Biotechnology, Genetics, Healthcare, Health Care, Therapeutics
- Solid Biosciences · Biotechnology, Genetics, Healthcare, Health Care, Therapeutics
- Elevation Oncology · Biotechnology, Genetics, Healthcare, Health Care, Therapeutics
- VolitionRx · Biotechnology, Genetics, Health Care, Therapeutics
- Verrica · Biotechnology, Healthcare, Health Care, Therapeutics
About Passage Bio: questions and answers
What does Passage Bio do?
Passage Bio, Inc. (NASDAQ: PASG) is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases.
Where is Passage Bio headquartered?
Passage Bio is headquartered in Philadelphia, United States.
How many employees does Passage Bio have?
Passage Bio has about 83 employees.
Has Passage Bio raised funding?
Yes. Fundz has recorded 2 funding events for Passage Bio. The most recent, Seed of $4.0M, was in Feb 2022.
Who leads Passage Bio?
Will Chou is a Chief Executive Officer at Passage Bio.
What is the latest news on Passage Bio?
On Sep 02, 2026, SEC 8-K (1.01): On September 2, 2026, Passage Bio, Inc. entered into an Amended and Restated Merger Agreement with Peregrine Merger Sub, Inc., a wholly owned subsidiary of the Company, and Remix Therapeutics, Inc. This agreement involves a strategic merger designed to advance Passage Bio's capabilit
Is Passage Bio a public company?
Yes. Passage Bio is publicly traded under the ticker PASG.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy